This is all a game Sarepta is far from being over looked.This is called not being to favorite to one company easy .Just see what comes about here with in 3 weeks or sooner.
person is at NIH today being treated with a classified drug. humm
amd why come out with it now unless it is a super big reason...think about it.
The primates were given many times the lethal dose of ebola and still had a big survival rate .The ebola infected humans are very light when compared to the doses applied to to primates.Please do your research before you comment for your motives..............XXXXXXXXXXXXXXXXX-------
Tthe primates were given many times the lethal dose of ebola and still had a big survival rate .the ebola infected humans are very light when compared to the doses applied to to primates.please do your research before you comment for your motives.
Sarepta therapeutics announces publication of Ebola and Marburg phase I clinical study results in antimicrobial agents and chemotherapy Full Text
Sarepta Therapeutics, 10/17/2014 Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA–based therapeutics, announced the publication of results from two single ascending–dose studies that demonstrated no clinical or toxicologic safety concerns with the company's drug candidates for the treatment of Ebola and Marburg virus, respectively.
EUA ...........this is why it came from left field
PMO-Based Platform Chemistries Used by AVI to Design and Manufacture Novel RNA-Based Drug Candidates Against Both Undisclosed Bacterial and Viral Targets
BOTHELL, WA--(Marketwire - Jun 16, 2011) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, and the Naval Medical Research Center (NMRC) in Silver Spring, MD, today announced the successful completion of a formal rapid-response exercise conducted by the Joint Project Manager Transformational Medical Technologies (JPM-TMT) of the Defense Threat Reduction Agency (DTRA). The exercise involved two undisclosed bacterial and viral threats and exhibited AVI's continued success in the development of a credible rapid response capability utilizing its RNA-based therapeutic technologies against pathogenic threats. Previously, AVI successfully completed its first formal rapid-response exercise against the pandemic H1N1 influenza virus (swine flu) in 2009 and one against the dengue virus in 2010.
The key outcome of this newest rapid response exercise was AVI's simultaneous conception, design and manufacture in 18 days of two novel RNA-based drug candidates, one against a gram negative bacterial target and the second against a viral target. The drug candidates use AVI's proprietary phosphorodiamidate morpholino oligomer (PMO) technologies, including PMOplus™, a positively charged version of its intrinsically charge-neutral PMO chemistry. This exercise is part of JPM-TMT 's and AVI's ongoing research efforts to develop and refine an efficient rapid-response capacity that includes the capability of responding to a real-world emerging infectious disease or biological threat by rapidly identifying the threat, designing and producing therapeutic candidates against the threat, and then evaluating the preclinical efficacy of therapeutic candidates.
"By addressing two pathogenic threats simultaneously, including for the first time a bacterial threat, this exercise further tested AVI's demonstrated ability to
just about any single strand virus ''do a sequence and get the drug made from Sarepta's platform.See rapid response done by us army and Avi/Sarepta
seems like we may see the 52 week high faster than we think....